#30 NEURO Part-1 Neurological Therapies CE 1.5 Total | 0.5 of which are Pharm Inflammation, Healing and Incorporation of Natural Therapies Topic Outline: 1. Key concepts in function Nutrition – Cell Support – Neurotransmission – Balance 2. Primary pathogenesis – Inflammation – Malnutrition – Imbalance 3. Treating / correcting imbalance …
#02 Neuroinflammation, Histamine and other Inflammatory Mediators CE 1.5 Total | 0.75 of which are Pharm “This webinar discusses histamine actions in the body, peripherally and in CNS. Histamine metabolism, elimination pathways and necessary nutrients for optimal pathway function. Methylation and histamine, interactions between Glutamate and histamine and leaky gut and leaky Blood Brain Barrier …
#02 Neuroinflammation, Histamine and other Inflammatory Mediators Read More »
#54 NEURO Part-5 Neurological Manifestations in Chronic patients – Assessments and Management CE 1.5 Total | 1.0 of which are Pharm Although a chronic illness may not seem to be happening in the body many patients have neurological manifestations which can be both surprising as well as difficult to find and treat. These can be …
#52 NEURO Part-4 Neurological Autoimmunity – Part 2 of 2 CE 1.5 Total | 1.0 of which are Pharm In this two-part webinar Dr. Anderson will break down neurological autoimmunity showing common and unique causes between un-diagnosable (global) neuro-inflammation, Parkinson’s, Alzheimers, MS, ALS and others. A look at assessment, repair strategies and real world potential …
#52 NEURO Part-4 Neurological Autoimmunity – Part 2 of 2 Read More »
#51 NEURO Part-3 Neurological Autoimmunity – Part 1 of 2 CE 1.5 Total | 1.0 of which are Pharm In this two-part webinar Dr. Anderson will break down neurological autoimmunity showing common and unique causes between un-diagnosable (global) neuro-inflammation, Parkinson’s, Alzheimers, MS, ALS and others. A look at assessment, repair strategies and real world potential …
#51 NEURO Part-3 Neurological Autoimmunity – Part 1 of 2 Read More »
#50 HBOT-2 Neurological and Cancer Primary Considerations CE 2.0 Total | 2.0 of which are Pharm Part-2 of the HBOT series with in dpeth information regarding HBOT and cancer as well as neurological illness
